CD70 and cancer: CD27 is a member of the tumor necrosis factor receptor superfamily and, in combination with its natural ligand CD70, activates the differentiation of T cells into effector and memory T cells and thus has potential as an immunomodulatory target in cancer therapy (Starzer and Berghoff, 2020).